TERMINATED

BurstDR Stimulation for Painful Diabetic Neuropathy

Conditions

Painful Diabetic Neuropathy neurostimulation spinal cord stimulation burst stimulation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to demonstrate treatment outcomes of Painful Diabetic Neuropathy (PDN) patients treated with BurstDRTM Spinal Cord Dorsal Column Stimulator (SCS) along with conservative medical management per standard of care.

Official Title

BurstDRTM Spinal Cord Dorsal Column Stimulation for Painful Diabetic Neuropathy

Quick Facts

Study Start:2023-07-03

Study Completion:2025-10-06

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:TERMINATED

Study ID

NCT05985291

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:22 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Diagnosis of lower extremity Painful Diabetic Neuropathy (PDN) with symptoms for at least a year prior to signing the consent form * PDN refractory to FDA approved medications: duloxetine, pregabalin, tapentadol, and capscaicin * Lower limb pain intensity of 5 cm or more on a 10-cm visual analogue scale (VAS) * HbA1c ≤10% * BMI \<45 kg/m2 * Be 22 years of age or older at the time of enrollment * Be an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician * Be capable of subjective evaluation, able to read and understand English-written questionnaires, and able to read, understand and sign the written informed consent in English * Be willing and capable of giving informed consent * Be willing and able to comply with study-related requirements, procedures, and scheduled visits * Have adequate cognitive ability to use a patient programmer and recharger as determined by the Investigator * Be on a stable analgesic regimen, as determined by the Investigator, for at least 30 days prior to assessing pain intensity, and be willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device * Have stable neurological status measured by motor, sensory and reflex function as determined by the investigator	* Current daily opioid dosage greater than 120 mg morphine equivalents * Have an average pain intensity of ≥ 3 out of 10 cm on the VAS in the upper extremities due to diabetic neuropathy at enrollment * Have a diagnosis of a lower limb mononeuropathy (e.g., causalgia and tibial or peroneal neuropathies), have had a lower limb amputation other than toes due to diabetes, or have large (≥3 cm) and/or gangrenous ulcers of the lower limbs. * Have a current diagnosis of a progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, Complex Regional Pain Syndrome, acute herniating disc, severe spinal stenosis and brachial plexus injury, as determined by the Investigator * Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, low platelet count, severely diminished functional capacity due to underlying cardiac/pulmonary disease, symptomatic uncontrolled hypertension, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure, as determined clinically by the Investigator * Be benefitting from an interventional procedure and/or surgery to treat lower limb pain (Subjects should be enrolled at least 30 days from last benefit). * Have an existing intrathecal pain pump and/or another active implantable device such as a pacemaker * Have a condition currently requiring or likely to require the use of diathermy or MRI that is inconsistent with ProclaimTM system guidelines in the Physician's Manual * Have either a metastatic malignant neoplasm or untreated local malignant neoplasm * Have a life expectancy of less than one year * Have within 6 months of enrollment a significant untreated addiction to dependency producing medications, alcohol or illicit drugs * Be concomitantly participating in another clinical study * Be involved in an injury claim under current litigation * Be a recipient of temporary Social Security Disability Insurance (SSDI) benefits due to chronic pain * Have a pending or approved worker's compensation claim * Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance with intervention and/or ability to evaluate treatment outcome, as determined by a psychologist in the last 12 months

Inclusion Criteria

Exclusion Criteria

* Diagnosis of lower extremity Painful Diabetic Neuropathy (PDN) with symptoms for at least a year prior to signing the consent form
* PDN refractory to FDA approved medications: duloxetine, pregabalin, tapentadol, and capscaicin
* Lower limb pain intensity of 5 cm or more on a 10-cm visual analogue scale (VAS)
* HbA1c ≤10%
* BMI \<45 kg/m2
* Be 22 years of age or older at the time of enrollment
* Be an appropriate candidate for the surgical procedures required in this study based on the clinical judgment of the implanting physician
* Be capable of subjective evaluation, able to read and understand English-written questionnaires, and able to read, understand and sign the written informed consent in English
* Be willing and capable of giving informed consent
* Be willing and able to comply with study-related requirements, procedures, and scheduled visits
* Have adequate cognitive ability to use a patient programmer and recharger as determined by the Investigator
* Be on a stable analgesic regimen, as determined by the Investigator, for at least 30 days prior to assessing pain intensity, and be willing to stay on those medications with no dose adjustments until activation of the permanently implanted SCS device
* Have stable neurological status measured by motor, sensory and reflex function as determined by the investigator

* Current daily opioid dosage greater than 120 mg morphine equivalents
* Have an average pain intensity of ≥ 3 out of 10 cm on the VAS in the upper extremities due to diabetic neuropathy at enrollment
* Have a diagnosis of a lower limb mononeuropathy (e.g., causalgia and tibial or peroneal neuropathies), have had a lower limb amputation other than toes due to diabetes, or have large (≥3 cm) and/or gangrenous ulcers of the lower limbs.
* Have a current diagnosis of a progressive neurological disease such as multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, rapidly progressive arachnoiditis, brain or spinal cord tumor, central deafferentation syndrome, Complex Regional Pain Syndrome, acute herniating disc, severe spinal stenosis and brachial plexus injury, as determined by the Investigator
* Have a current diagnosis or condition such as a coagulation disorder, bleeding diathesis, platelet dysfunction, low platelet count, severely diminished functional capacity due to underlying cardiac/pulmonary disease, symptomatic uncontrolled hypertension, progressive peripheral vascular disease or uncontrolled diabetes mellitus that presents excess risk for performing the procedure, as determined clinically by the Investigator
* Be benefitting from an interventional procedure and/or surgery to treat lower limb pain (Subjects should be enrolled at least 30 days from last benefit).
* Have an existing intrathecal pain pump and/or another active implantable device such as a pacemaker
* Have a condition currently requiring or likely to require the use of diathermy or MRI that is inconsistent with ProclaimTM system guidelines in the Physician's Manual
* Have either a metastatic malignant neoplasm or untreated local malignant neoplasm
* Have a life expectancy of less than one year
* Have within 6 months of enrollment a significant untreated addiction to dependency producing medications, alcohol or illicit drugs
* Be concomitantly participating in another clinical study
* Be involved in an injury claim under current litigation
* Be a recipient of temporary Social Security Disability Insurance (SSDI) benefits due to chronic pain
* Have a pending or approved worker's compensation claim
* Have evidence of an active disruptive psychological or psychiatric disorder or other known condition significant enough to impact perception of pain, compliance with intervention and/or ability to evaluate treatment outcome, as determined by a psychologist in the last 12 months

Contacts and Locations

Principal Investigator

Mansoor Aman, MD

PRINCIPAL_INVESTIGATOR

Aurora Healthcare

Study Locations (Sites)

Aurora Health Oshkosh

Oshkosh, Wisconsin, 54914

United States

Collaborators and Investigators

Sponsor: Wake Forest University Health Sciences

Mansoor Aman, MD, PRINCIPAL_INVESTIGATOR, Aurora Healthcare

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-07-03

Study Completion Date2025-10-06

Study Record Updates

Study Start Date2023-07-03

Study Completion Date2025-10-06

Terms related to this study

Keywords Provided by Researchers

neurostimulation
spinal cord stimulation
burst stimulation

Additional Relevant MeSH Terms

Painful Diabetic Neuropathy